51
Citations
35
Journals
2010
First Cited
2022
Last Cited

Articles citing This Document (Page 1 of 2)

ArticleJournalYear
Targeted therapy for breast cancer: An overview of drug classes and outcomes2022
Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China
Radiotheranostics in oncology: current challenges and emerging opportunitiesNature Reviews Clinical Oncology
Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction.Current Oncology Reports2022
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.Npj Breast Cancer2022
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.BioDrugs2022
Cancer Immunotherapies: What the Perioperative Physician Needs to Know.Current Oncology Reports2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.Investigational New Drugs2022
The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.Molecular Diagnosis and Therapy2022
Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.Advances in Therapy2022
Novel Therapies to Overcome HER2 Therapy Resistance in Breast CancerResistance To Targeted Anti-cancer Therapeutics2019
Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative reviewBreast Cancer Research and Treatment2021
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is nowNpj Breast Cancer2021
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence TrialBioDrugs2021
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancerExpert Review of Pharmacoeconomics and Outcomes Research2021
Trastuzumab administration during pregnancy: an updateBMC Cancer2021
Immunogenicity Risk Profile of NanobodiesFrontiers in Immunology2021
Facile protein conjugation of platinum for light-activated cytotoxic payload releaseChemical Communications2021
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjectsCancer Chemotherapy and Pharmacology2021
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysisBreast Cancer Research and Treatment2020
Risks at the Intersection of Research and Oncology NursingSeminars in Oncology Nursing2020
Commentary on ICH guideline on genomic sampling and data management-enabling opportunities in drug development and patient treatmentBritish Journal of Clinical Pharmacology2020
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancerCardio-Oncology2020
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trialsCancer Chemotherapy and Pharmacology2020
Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilarsAnalytical and Bioanalytical Chemistry2020
Current Considerations on Characterization of Immune Response to Multi-Domain BiotherapeuticsBioDrugs2020
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding StudyJournal of Clinical Pharmacology2019
Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast CancerOncologist2019
Clinical development of CT-P6 in HER2 positive breast cancerExpert Opinion on Biological Therapy2019
Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trialCancer Communications2019
Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer TherapyJACC: Cardiovascular Imaging2018
In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous InfusionBioDrugs2018
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unitEuropean Journal of Obstetrics, Gynecology and Reproductive Biology2018
Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry studyAsia-Pacific Journal of Clinical Oncology2017
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjectsCancer Chemotherapy and Pharmacology2017
Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based TherapyHeart Failure Clinics2017
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and LaunchClinical and Translational Science2017
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancerInternal and Emergency Medicine2016
Potential Sources of Inter-Subject Variability in Monoclonal Antibody PharmacokineticsClinical Pharmacokinetics2016
Trastuzumab in the Treatment of Breast CancerBioDrugs2016
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical OncologyAmerican Journal of Clinical Pathology2016
Cardiovascular prevention in the cancer survivorCurrent Atherosclerosis Reports2015
Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference ConsiderationsTherapeutic Innovation and Regulatory Science2014
Cardiac toxicity in cancer survivorsCancer2013
Role of Pharmacogenetics in Registration Processes2012
Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenograftsAAPS Journal2012
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Oncologist2012
HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridizationAmerican Journal of Clinical Pathology2012
Issues facing therapeutic monoclonal antibodies for the future2012
Trastuzumab in HER2-positive metastatic gastric cancer: profile reportBioDrugs2011